RJA
MCRB icon

Raymond James & Associates’s Seres Therapeutics MCRB Stock Holding History

Raymond James & Associates’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-503
Closed -$48.1K – 3879
2023
Q2 		$48.1K Buy
+503
New +$54.7K ﹤0.01% 3710
2022
Q4 		– Sell
-1,017
Closed -$131K – 4003
2022
Q3 		$131K Buy
1,017
+72
+8% +$7.37K ﹤0.01% 3556
2022
Q2 		$65K Buy
+945
New +$81.4K ﹤0.01% 3755
2021
Q3 		– Sell
-660
Closed -$315K – 4202
2021
Q2 		$315K Buy
+660
New +$278K ﹤0.01% 3408
2020
Q3 		– Sell
-759
Closed -$72K – 3649
2020
Q2 		$72K Buy
+759
New +$66.6K ﹤0.01% 3337
2016
Q2 		– Sell
-408
Closed -$217K – 3071
2016
Q1 		$217K Buy
+408
New +$213K ﹤0.01% 2528

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Raymond James & Associates's MCRB Position: Q3 2023 in Review

Raymond James & Associates sold out of Seres Therapeutics (MCRB) in Q3 2023, closing a stake of 503 shares — an estimated $48.1K sold.

Raymond James & Associates first reported a position in MCRB in Q1 2016 and held it in 6 quarters. The position peaked at $315K in Q2 2021. 134 funds tracked by Wall St. Rank hold MCRB as of Q3 2023.

  • Raymond James & Associates reported no remaining Seres Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Raymond James & Associates sold 503 Seres Therapeutics shares in Q3 2023, an estimated $48.1K.
  • Raymond James & Associates first reported a position in Seres Therapeutics in Q1 2016 and held it in 6 quarters.
  • Raymond James & Associates's Seres Therapeutics position peaked at $315K in Q2 2021.
  • 134 funds tracked by Wall St. Rank held Seres Therapeutics as of Q3 2023.

Based on Raymond James & Associates's 13F filing for Q3 2023, filed 24 Oct 2023.